Identification of Novel Inflammation-related Biomarkers for Early Detection of Anthracycline-induced Cardiotoxicity in Breast Cancer Patients

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05298072

Enrollment

180

Registered

2022-03-28

Start date

2022-04-30

Completion date

2023-12-31

Last updated

2022-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Cardiotoxicity, Heart Failure

Brief summary

This study aims to identify possible set of inflammatory biomarkers before, during and after anthracycline-based chemotherapy in breast cancer patients to identify (sub)clinical chemotherapy-related cardiac dysfunctionCRCD to identify patients who would benefit from additional cardioprotective therapy.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* initial diagnosis of breast cancer * planned Anthracycline-based therapy * first-line chemotherapy * first visit before initiation of chemotherapy

Exclusion criteria

* previous chemotherapy * medical history of cardiac disease * inflammation-modulating medication * medication with RAS inhibitors * pregnancy * autoimmune disease * drug addictions * unwilling or unable to provide informed consent

Design outcomes

Primary

Measure	Time frame	Description
Cardiotoxicity during observational period	continuous evaluation during observational period of 12 months	Defined according to IC-OS 2021 Consensus Criteria

Outcome results